Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Narpala

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccineLela Kardava, Nicholas Rachmaninoff, William W Lau, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
The New England Journal of Medicine|November 1, 2022
Safety and Efficacy of a Monoclonal Antibody against Malaria in MaliKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Cell Reports|April 7, 2021
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer baseAngela R Corrigan, Hongying Duan, Cheng Cheng, et al.
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Iscience|August 9, 2023
Soluble prefusion-closed HIV-envelope trimers with glycan-covered basesAdam S Olia, Cheng Cheng, Tongqing Zhou, et al.
Nature Structural & Molecular Biology|December 23, 2015
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designJason Gorman, Cinque Soto, Max M Yang, et al.
Medrxiv : the Preprint Server for Health Sciences|April 8, 2025
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled TrialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccineLela Kardava, Nicholas Rachmaninoff, William W Lau, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
The New England Journal of Medicine|November 1, 2022
Safety and Efficacy of a Monoclonal Antibody against Malaria in MaliKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Cell Reports|April 7, 2021
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer baseAngela R Corrigan, Hongying Duan, Cheng Cheng, et al.
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Iscience|August 9, 2023
Soluble prefusion-closed HIV-envelope trimers with glycan-covered basesAdam S Olia, Cheng Cheng, Tongqing Zhou, et al.
Nature Structural & Molecular Biology|December 23, 2015
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designJason Gorman, Cinque Soto, Max M Yang, et al.
Medrxiv : the Preprint Server for Health Sciences|April 8, 2025
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled TrialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Pageof 5